Search Within

Tara Jeanne O'Donohue

Formats
  1. Meeting Abstract (10)
  2. Journal Article (6)
  3. Review (1)
Groups
  1. Pediatrics, Department of (15)
  2. Center for Hematologic Malignancies (12)
  3. Department of Medicine (10)
  4. Sarcoma Service (Pediatrics) (10)
  5. Sloan Kettering Institute Postdocs (10)
  6. Tow Center for Developmental Oncology (TCDO) (10)

More Groups

People
  1. Neerav Shukla (9)
  2. Filemon Dela Cruz (8)
  3. Andrew Kung (7)
  4. Julia Glade Bender (7)
  5. Emily Slotkin (6)
  6. Michael Ortiz (6)

More People

Years
  1. 2025 (2)
  2. 2024 (2)
  3. 2023 (2)
  4. 2022 (4)
  5. 2021 (3)
  6. 2020 (1)

More Years

Publications
  1. Journal of Clinical Oncology (3)
  2. Pediatric Blood and Cancer (3)
  3. Cancer Research (2)
  4. Blood (1)
  5. Clinical Cancer Research (1)
  6. Current Opinion in Pediatrics (1)

More Publications

Publishers
  1. American Association for Cancer Research (4)
  2. American Society of Clinical Oncology (3)
  3. Wiley Periodicals, Inc (3)
  4. American Society of Hematology (1)
  5. Elsevier Inc. (1)
  6. Lippincott Williams & Wilkins (1)

More Publishers

Results (17)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A phase 1/2, open-label study of repotrectinib in pediatric and young adult patients with advanced or metastatic malignancies harboring ALK, ROS1, or NTRK1-3 alterations
    Meeting Abstract

    Dubois, S.; O'Donohue, T.; Kang, H. J.; Federman, N.; Watt, T.; Cluster, A.; Zimmerman, Z.; Trone, D.; Mascarenhas, L.
    Pediatric Blood and Cancer (2021)

    Fulltext@MSK | Save
  • Feasibility and clinical utility of cancer whole genome and transcriptome sequencing for pediatric and young adult solid tumors
    Meeting Abstract

    Shukla, N.; Levine, M.; Gundem, G.; Spitzer, B.; Gutierrez-Abril, J.; Bouvier, N.; Arango Ossa, J. E.; Medina-Martinez, J.; Stockfisch, E.; O'Donohue, T.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Translational strategies for repotrectinib in neuroblastoma
    Journal Article

    O'Donohue, T. J.; Ibáñez, G.; Coutinho, D. F.; Mauguen, A.; Siddiquee, A.; Rosales, N.; Calder, P.; Ndengu, A.; You, D.; Long, M.; more...
    Molecular Cancer Therapeutics (2021)

    Fulltext@MSK | Save
  • TPX-0005 (Repotrectinib), a next-generation ALK/ROS1/NTRK1-3 inhibitor, has potent antiproliferative and anti-tumor activity as monotherapy and in combination with chemotherapy in neuroblastoma cell lines and pediatric patient derived xenograft models
    Meeting Abstract

    O'Donohue, T.; Ibáñez, G.; Mauguen, A.; Siddiquee, A.; Rosales, N.; Calder, P.; Ndengu, A.; Roberts, S.; Dela Cruz, F.; Kung, A.
    European Journal of Cancer (2020)

    Fulltext@MSK | Save
  • Clinical impact of ALK mutations in neuroblastoma
    Meeting Abstract

    O'Donohue, T.; Gulati, N.; Shukla, N.; Roberts, S.; Basu, E.; Kushner, B.; Cheung, N. K.; Modak, S.
    Pediatric Blood and Cancer (2019)

    Fulltext@MSK | Save
  • Outcome of children and adolescents with relapsed Hodgkin lymphoma treated with high-dose therapy and autologous stem cell transplantation: The Memorial Sloan Kettering Cancer Center experience
    Journal Article

    Giulino-Roth, L.; O’Donohue, T.; Chen, Z.; Trippett, T. M.; Klein, E.; Kernan, N. A.; Kobos, R.; Prockop, S. E.; Scaradavou, A.; Shukla, N.; more...
    Leukemia and Lymphoma (2018)

    Fulltext@MSK | Save
  • Long-term follow up of pediatric patients with Hodgkin lymphoma treated with high dose therapy and autologous stem cell transplantation
    Meeting Abstract

    Roth, L. G.; O'Donohue, T.; Trippett, T.; Klein, E.; Kernan, N. A.; Kobos, R.; Prockop, S.; Scaradavou, A.; Shukla, N.; Steinherz, P. G.; more...
    Blood (2015)

    Fulltext@MSK | Save